<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108964</url>
  </required_header>
  <id_info>
    <org_study_id>CEGF816X2101</org_study_id>
    <secondary_id>2013-004482-14</secondary_id>
    <nct_id>NCT02108964</nct_id>
  </id_info>
  <brief_title>A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies</brief_title>
  <official_title>A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (Phase l
      part) of EGF816 and to investigate the anti-tumor activity of EGF816 (Phase II part).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 14, 2001</start_date>
  <completion_date type="Anticipated">September 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicity (DLT) Phase I Part</measure>
    <time_frame>First 28 days of dosing</time_frame>
    <description>Maximum tolerated dose (MTD) or Recommended Phase II dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) Phase II Part</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) determined by Blinded Independent Review Committee (BIRC) assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (Phase I &amp; Phase II Parts)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>PFS is defined as time from date of first dose of study treatment to date of first documented disease progression or death due to any cause determined by by Investigator assessment in accordance to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (Phase I &amp; II Parts)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>DOR is defined as the time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause determined by Investigator assessment in accordance to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration vs. time profiles, plasma PK parameters (Phase I Part &amp; Phase II part)</measure>
    <time_frame>12 weeks (Cycle 1 Day 1,2,8, 15; Cycle 2 Day 1, 2; Cycle 3 Day 1; Cycle 4 Day 1</time_frame>
    <description>To characterize the PK properties of EGF816 and metabolite LMI258 (Phase I &amp; II parts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and on-treatment immunohistochemistry of EGFR pathway molecules (prior to PA05)</measure>
    <time_frame>15 days (Pre-screening, screening and Cycle 1 Day 15)</time_frame>
    <description>To assess the tumor EGFR signaling inhibition by EGF816</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (Phase I &amp; II Parts)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>ORR is defined as proportion of patients with best overall response of (PR+CR) determined by Investigator assessment assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (Phase I &amp; II Parts)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>DCR is defined as the proportion of patients with best overall response of CR, PR, or SD determined by Investigator assessment assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (Phase I &amp; II Parts)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>TTR is defined as the time from the date of the first dose to the date of first documented response (CR or PR) determined by Investigator assessment assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence and severity of AEs, changes in laboratory values, vital signs &amp; ECGs. Tolerability: Dose interruptions &amp; reductions (Phase I &amp; II Parts)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>Assessment of the safety and tolerability of EGF816 will be performed continuously during the treatment phase and 30 days after discontinuation of the study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (Phase II Part)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>DOR is defined as the time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause determined by Blinded Independent Review Committee in accordance to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (Phase II Part)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>DCR is defined as the proportion of patients with best overall response of CR, PR, or SD determined by Blinded Independent Review Committee (BIRC) in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (Phase II Part)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>Progression-free survival (PFS). PFS is defined as time from date of first dose of study treatment to date of first documented disease progression or death due to any cause determined by Blinded Independent Review Committee in accordance to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (Phase II Part)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>TTR is defined as as the time from the date of first dose of study treatment to the date of first documented response (CR or PR) determined by Blinded Independent Review Committee (BIRC) in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Phase II Part)</measure>
    <time_frame>At least 24 weeks</time_frame>
    <description>OS is defined as the time from first dose of the study treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Advanced Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 patients with EGFR mutations (Recruitment is completed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least 40 patients who have advanced NSCLC and EGFR activating mutations (i.e. L858R and/or ex19del). These patients must be treatment na√Øve and must have not received any systemic antineoplastic therapy for advanced NSCLC. Note: patients who have received no more than 1 cycle of antineoplastic therapy in the advanced setting are allowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGF816</intervention_name>
    <description>EGF816 will be dosed once daily. On the first day of each treatment Cycle, the patient receives an adequate drug supply for self-administration at home. The investigator must emphasize compliance with the study treatment and will instruct the patient to take EGF816 exactly as prescribed.</description>
    <arm_group_label>Phase I part</arm_group_label>
    <arm_group_label>Phase II part</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (For all patients unless otherwise specified)

          -  Histologically or cytologically confirmed locally advanced (stage IIIB not amenable to
             definitive multi-modality therapy including surgery) or metastatic (stage IV) EGFR
             mutant NSCLC.

          -  Patients with controlled brain metastases

          -  ECOG performance status: Phase I part: 0, 1, or 2; Phase II part: 0 or 1

          -  Presence of at least one measurable lesion according to RECIST 1.1

          -  Patients who are either HBsAg positive or HBV-DNA positive must be willing and able to
             take antiviral therapy 1-2 weeks prior to 1st dose of EGF816 treatment and continue on
             antiviral therapy for at least 4 weeks after the last dose of EGF816

          -  Patients must have negative hepatitis C antibody (HCV-Ab) or positive HCV-Ab but
             undetectable level of HCV-RNA. Note: patients with detectable HCV-RNA are not eligible
             for the study.

          -  For Phase I: patients must have failed no more than 3 lines of any systemic
             antineoplastic therapy for advanced NSCLC, including EGFR-TKI

          -  For Phase II: patients must be na√Øve from any systemic antineoplastic therapy in the
             advanced setting. Patients who have failed no more than 1 cycle of systemic
             antineoplastic therapy in the advanced setting are allowed.

        Exclusion criteria: (Applies to all patients unless otherwise specified)

          -  Patients with a history or presence of ILD or interstitial pneumonitis, including
             clinically significant radiation pneumonitis (i.e. affecting activities of daily
             living or requiring therapeutic intervention)

          -  Presence or history of another malignancy

          -  Undergone a bone marrow or solid organ transplant

          -  Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is not
             mandatory)

          -  Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use
             at the time of study entry except for control of brain metastases, topical
             applications, inhaled sprays, eye drops or local injections

          -  Patients with clinically significant, uncontrolled heart disease

          -  Any prior therapies ‚â§ 4 weeks prior to the first dose of study treatment

          -  Patients who are receiving treatment with medications that are known to be strong
             inhibitors or inducers of CYP3A4/5 and cannot be discontinued 1 week prior to the
             start of EGF816 treatment and for the duration of the study.

          -  Patients who have impairment of GI function or GI disease that may significantly alter
             the absorption of EGF816 (e.g., ulcerative diseases, uncontrolled nausea, vomiting,
             diarrhea, or malabsorption syndrome)

          -  Patients who are receiving treatment with any enzyme-inducing anticonvulsant that
             cannot be discontinued at least 1 week before first dose of study treatment, and for
             the duration of the study

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception

          -  Sexually active males unless they use a condom during intercourse while taking drug
             and for 3 months after stopping treatment Other protocol-defined inclusion and
             exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Mass General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Oncology Department</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan ROC</state>
        <zip>10041</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>China</country>
    <country>France</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Non-small Cell Lung Cancer EGFRmut</keyword>
  <keyword>EGFR TKIs (EGF816)</keyword>
  <keyword>acquired T790M mutation</keyword>
  <keyword>de novo T790M mutation</keyword>
  <keyword>EGFR TKI activating mutation (i.e. L858R or ex19del)</keyword>
  <keyword>Treatment naive advanced NSCLC with EGFR activating mutations</keyword>
  <keyword>Locally advanced NSCLC (Stage IIIB NSCLC not amenable to definitive multi-modality therapy including surgery)</keyword>
  <keyword>Metastatic NSCLC refers to Stage IV NSCLC</keyword>
  <keyword>1st line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

